What is the reimbursement price of Ripotinib in medical insurance?

Repotrectinib, as a new generation of multi-target tyrosine kinase inhibitors, has demonstrated significant efficacy and clinical value in the treatment of patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in recent years. As my country attaches great importance to precision treatment of tumors, Ripotinib has been officially launched in China and included in the national medical insurance directory. This not only provides patients with more treatment options, but also significantly reduces the economic burden of medication and promotes the popularization and standardization of targeted therapy.

Specifically, the main specifications of Ripotinib in the Chinese market are40mg*120 pills per box, and the price of a single box is about more than 5,000 yuan. Although prices vary among different regions and medical institutions, in general, the inclusion of medical insurance greatly reduces the financial pressure on patients. The coverage of this drug in the National Reimbursement Directory not only reflects the recognition of innovative drugs, but also reflects the government’s policy direction of promoting the fair distribution of high-quality medical resources. Patients can obtain part of the drug reimbursement through medical insurance reimbursement, which reduces the financial burden caused by long-term medication. Especially for non-small cell lung cancer, a disease that requires continuous treatment, medical insurance support is particularly critical.

The specific ratio and policy of medical insurance reimbursement may vary from province to city. In some areas, the reimbursement ratio can reach more than 70%. However, patients still need to consult the local medical insurance agency for detailed reimbursement policies and self-payment ratios before actual treatment. In addition, the use of repotinib is generally based on clear genetic test results to ensure that the patient is ROS1 positive and complies with the principle of precise medication. As an important part of precision medicine, genetic testing usually requires patients to pay for it out of their own pocket, but its results directly affect the rational use and therapeutic effect of medical insurance drugs, making it an important part of the clinical path.

Reference materials:https://www.drugs.com/mtm/repotrectinib.html